Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats

Pius Maliakal, Maen Abdelrahim, Umesh T. Sankpal, Cima Maliakal, Cheryl H. Baker, Stephen Safe, Luis J. Herrera, Ala Abudayyeh, Sumanth Kaja, Riyaz Basha

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The primary objective of this study is to identify small molecules that target critical transcription factors for potential application in the chemoprevention of esophageal cancer. Specificity proteins (Sp) play a critical role in the growth and metastasis of several malignancies including esophageal cancer. Researchers at the M. D. Anderson Cancer Center Orlando Cancer Research Institute have reported previously that tolfenamic acid (TA) inhibits cancer cell proliferation and tumor growth through the degradation of Sp1, Sp3, and Sp4. We evaluated the chemopreventive properties of TA against esophageal tumorigenesis in N-nitrosomethylbenzylamine (NMBA)- induced murine tumor model. Fischer-344 rats were treated with NMBA (0.5 mg/kg s.c. 3 times a week) for 5 weeks to initiate the tumor formation, and then treated with 50 mg/kg TA from week 6 through week 25. Tumor incidence, tumor multiplicity (number of papilloma per rat), and tumor volume were evaluated after 25 weeks. All rats in the control group that received only NMBA developed lesions (100% incidence), while the TA-treated group showed significantly lower (33%) tumor incidence and tumor multiplicity. Furthermore, the tumor volume was significantly diminished in the TA-treated group when compared with the control group. Using small molecules such as TA to target key transcription factors associated with tumorigenesis for the prevention of esophageal malignancies is a new and promising strategy. Results of the current study provide evidence that TA, when given orally after tumor initiation, can significantly suppress tumorigenesis induced by carcinogenic nitrosamines in rats. These appealing results demonstrate that TA may potentially serve as an effective chemopreventive agent in patient populations vulnerable to esophageal cancer.

Original languageEnglish
Pages (from-to)853-861
Number of pages9
JournalInvestigational New Drugs
Volume30
Issue number3
DOIs
StatePublished - 1 Jun 2012

Fingerprint

Carcinogenesis
Neoplasms
Esophageal Neoplasms
nitrosobenzylmethylamine
Tumor Burden
tolfenamic acid
Incidence
Transcription Factors
Nitrosamines
Control Groups
Inbred F344 Rats
Chemoprevention
Papilloma
Proxy
Vulnerable Populations
Growth
Research Personnel
Cell Proliferation
Neoplasm Metastasis

Keywords

  • Esophageal cancer
  • Esophageal cancer prevention
  • N-nitrosomethylbenzylamine
  • Sp1
  • Tolfenamic acid
  • c-Met

Cite this

Maliakal, Pius ; Abdelrahim, Maen ; Sankpal, Umesh T. ; Maliakal, Cima ; Baker, Cheryl H. ; Safe, Stephen ; Herrera, Luis J. ; Abudayyeh, Ala ; Kaja, Sumanth ; Basha, Riyaz. / Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. In: Investigational New Drugs. 2012 ; Vol. 30, No. 3. pp. 853-861.
@article{a7673802f6944ddbb28c82df22bbab4a,
title = "Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats",
abstract = "The primary objective of this study is to identify small molecules that target critical transcription factors for potential application in the chemoprevention of esophageal cancer. Specificity proteins (Sp) play a critical role in the growth and metastasis of several malignancies including esophageal cancer. Researchers at the M. D. Anderson Cancer Center Orlando Cancer Research Institute have reported previously that tolfenamic acid (TA) inhibits cancer cell proliferation and tumor growth through the degradation of Sp1, Sp3, and Sp4. We evaluated the chemopreventive properties of TA against esophageal tumorigenesis in N-nitrosomethylbenzylamine (NMBA)- induced murine tumor model. Fischer-344 rats were treated with NMBA (0.5 mg/kg s.c. 3 times a week) for 5 weeks to initiate the tumor formation, and then treated with 50 mg/kg TA from week 6 through week 25. Tumor incidence, tumor multiplicity (number of papilloma per rat), and tumor volume were evaluated after 25 weeks. All rats in the control group that received only NMBA developed lesions (100{\%} incidence), while the TA-treated group showed significantly lower (33{\%}) tumor incidence and tumor multiplicity. Furthermore, the tumor volume was significantly diminished in the TA-treated group when compared with the control group. Using small molecules such as TA to target key transcription factors associated with tumorigenesis for the prevention of esophageal malignancies is a new and promising strategy. Results of the current study provide evidence that TA, when given orally after tumor initiation, can significantly suppress tumorigenesis induced by carcinogenic nitrosamines in rats. These appealing results demonstrate that TA may potentially serve as an effective chemopreventive agent in patient populations vulnerable to esophageal cancer.",
keywords = "Esophageal cancer, Esophageal cancer prevention, N-nitrosomethylbenzylamine, Sp1, Tolfenamic acid, c-Met",
author = "Pius Maliakal and Maen Abdelrahim and Sankpal, {Umesh T.} and Cima Maliakal and Baker, {Cheryl H.} and Stephen Safe and Herrera, {Luis J.} and Ala Abudayyeh and Sumanth Kaja and Riyaz Basha",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s10637-010-9622-0",
language = "English",
volume = "30",
pages = "853--861",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Maliakal, P, Abdelrahim, M, Sankpal, UT, Maliakal, C, Baker, CH, Safe, S, Herrera, LJ, Abudayyeh, A, Kaja, S & Basha, R 2012, 'Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats', Investigational New Drugs, vol. 30, no. 3, pp. 853-861. https://doi.org/10.1007/s10637-010-9622-0

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. / Maliakal, Pius; Abdelrahim, Maen; Sankpal, Umesh T.; Maliakal, Cima; Baker, Cheryl H.; Safe, Stephen; Herrera, Luis J.; Abudayyeh, Ala; Kaja, Sumanth; Basha, Riyaz.

In: Investigational New Drugs, Vol. 30, No. 3, 01.06.2012, p. 853-861.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats

AU - Maliakal, Pius

AU - Abdelrahim, Maen

AU - Sankpal, Umesh T.

AU - Maliakal, Cima

AU - Baker, Cheryl H.

AU - Safe, Stephen

AU - Herrera, Luis J.

AU - Abudayyeh, Ala

AU - Kaja, Sumanth

AU - Basha, Riyaz

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The primary objective of this study is to identify small molecules that target critical transcription factors for potential application in the chemoprevention of esophageal cancer. Specificity proteins (Sp) play a critical role in the growth and metastasis of several malignancies including esophageal cancer. Researchers at the M. D. Anderson Cancer Center Orlando Cancer Research Institute have reported previously that tolfenamic acid (TA) inhibits cancer cell proliferation and tumor growth through the degradation of Sp1, Sp3, and Sp4. We evaluated the chemopreventive properties of TA against esophageal tumorigenesis in N-nitrosomethylbenzylamine (NMBA)- induced murine tumor model. Fischer-344 rats were treated with NMBA (0.5 mg/kg s.c. 3 times a week) for 5 weeks to initiate the tumor formation, and then treated with 50 mg/kg TA from week 6 through week 25. Tumor incidence, tumor multiplicity (number of papilloma per rat), and tumor volume were evaluated after 25 weeks. All rats in the control group that received only NMBA developed lesions (100% incidence), while the TA-treated group showed significantly lower (33%) tumor incidence and tumor multiplicity. Furthermore, the tumor volume was significantly diminished in the TA-treated group when compared with the control group. Using small molecules such as TA to target key transcription factors associated with tumorigenesis for the prevention of esophageal malignancies is a new and promising strategy. Results of the current study provide evidence that TA, when given orally after tumor initiation, can significantly suppress tumorigenesis induced by carcinogenic nitrosamines in rats. These appealing results demonstrate that TA may potentially serve as an effective chemopreventive agent in patient populations vulnerable to esophageal cancer.

AB - The primary objective of this study is to identify small molecules that target critical transcription factors for potential application in the chemoprevention of esophageal cancer. Specificity proteins (Sp) play a critical role in the growth and metastasis of several malignancies including esophageal cancer. Researchers at the M. D. Anderson Cancer Center Orlando Cancer Research Institute have reported previously that tolfenamic acid (TA) inhibits cancer cell proliferation and tumor growth through the degradation of Sp1, Sp3, and Sp4. We evaluated the chemopreventive properties of TA against esophageal tumorigenesis in N-nitrosomethylbenzylamine (NMBA)- induced murine tumor model. Fischer-344 rats were treated with NMBA (0.5 mg/kg s.c. 3 times a week) for 5 weeks to initiate the tumor formation, and then treated with 50 mg/kg TA from week 6 through week 25. Tumor incidence, tumor multiplicity (number of papilloma per rat), and tumor volume were evaluated after 25 weeks. All rats in the control group that received only NMBA developed lesions (100% incidence), while the TA-treated group showed significantly lower (33%) tumor incidence and tumor multiplicity. Furthermore, the tumor volume was significantly diminished in the TA-treated group when compared with the control group. Using small molecules such as TA to target key transcription factors associated with tumorigenesis for the prevention of esophageal malignancies is a new and promising strategy. Results of the current study provide evidence that TA, when given orally after tumor initiation, can significantly suppress tumorigenesis induced by carcinogenic nitrosamines in rats. These appealing results demonstrate that TA may potentially serve as an effective chemopreventive agent in patient populations vulnerable to esophageal cancer.

KW - Esophageal cancer

KW - Esophageal cancer prevention

KW - N-nitrosomethylbenzylamine

KW - Sp1

KW - Tolfenamic acid

KW - c-Met

UR - http://www.scopus.com/inward/record.url?scp=84864366217&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9622-0

DO - 10.1007/s10637-010-9622-0

M3 - Article

C2 - 21197621

AN - SCOPUS:84864366217

VL - 30

SP - 853

EP - 861

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -